The Trump administration is negotiating deals with two major drug companies that could slash prices on popular weight-loss medications.

Sources tell ABC News that Novo Nordisk and Eli Lilly are in talks to offer their drugs for about $149 a month and have them covered for some Medicare patients.

That would mark a significant drop from current prices as a growing concern regarding rising health care costs is the increased use of expensive weight loss medications. A growing number of patients are utilizing glucagon-like peptide (GLP-1) drugs. While these medications have long been covered for treating diabetes, they typically haven't been covered for weight-loss purposes.

These drugs can cost over $1,000 per monthly dose.

RELATED STORY | Cost of health benefits expected to rise over

See Full Page